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PURPOSE: Screening for mutations in the entire Cystic Fibrosis gene (CFTR) of Brazilian infertile men with congenital absence
of vas deferens, in order to prevent transmission of CFTR mutations to offspring with the use of assisted reproductive technologies.
METHOD: Specific polymerase chain reaction (PCR) primers were designed to each of the 27 exons and splicing sites of interest
followed by single strand conformational polymorphism and Heteroduplex Analysis (SSCP-HA) in precast 12.5% polyacrylamide
gels at 7OC and 20OC. Fragments with abnormal SSCP migration pattern were sequenced.
RESULTS: Two novel missense mutations (S753R and G149W) were found in three patients (two brothers) together with the
IVS8-5T allele in hetrozygosis.
CONCLUSION: The available screenings for CF mutations do not include the atypical mutations associated to absence of vas
deferens and thus, when these tests fail to find mutations, there is still a genetic risk of affected children with the help of assisted
reproduction. We recommend the screening of the whole CFTR gene for these infertile couples, as part of the work-up before
assisted reproduction.
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INTRODUCTION
Cystic fibrosis (CF) is the most prevalent life-shorten-
ing autosomal recessive disorder in Caucasian patients of
European descent and is associated to mutations in the
Cystic Fibrosis Transmembrane Conductance Regulator
(CFTR) gene.1 Dysfunction of CFTR Cl- channel in the ge-
netic disease CF disrupts transepithelial ions transport and
mucociliary clearance in a variety of organs lined by epi-
thelia resulting in a wide-ranging of misleading clinical
manifestations that may include: pulmonary disease, pan-
creatic failure, meconium ileus, elevated levels of salt in
sweat and male infertility due to congenital bilateral ab-
sence of vas deferens (CBAVD).
Some patients may have all the classical manifestations
of CF from infancy and have a relatively poor prognosis,
while others have much milder or even atypical disease
manifestations, with single organ involvement, and accord-
ing to the World Health Organization2 should also be con-
sidered as CF patients. The CBAVD men without other CF
symptoms fall into this category.
Azoospermic CBAVD patients usually have normal sper-
matogenesis. The male gamete can be retrieved by Micro-
surgical Epididymal Sperm Aspiration (MESA) or Testicu-
lar Sperm Extraction (TESE) and used in assisted reproduc-
tive techniques such as intracytoplasmic sperm injection
(ICSI) allowing biological paternity to CBAVD patients.3,4
Today, screening for a panel of CFTR mutations is of-
fered to these men prior to ICSI, and includes only the most
common mutations found in CF patients of European and
North American origin. The atypical CBAVD phenotype,
however, is caused by milder mutations, most of them very
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rare or even not yet described, and thus not included in the
panel of CF mutations usually screened.
These facts lead us to undertake a complete analysis of
the entire CFTR gene in Brazilian patients with congeni-
tal absence of the vas deferens (CAVD) prior to ICSI, and
two novel mutations were identified in the patients stud-
ied. The high cost of the test, the anxiety of the couple to
be submitted to assisted reproduction and the unawareness
of the genetic risks involved are especial features of the ge-
netic counseling of these cases.
Methods: patients and procedures
The study was approved by our Institutional Ethics
Committee for Research Protocols.
After a brief explanation about the test and informed
consent signature, 4 mL of whole blood samples were drawn
from patients into EDTA vacuum tubes (Becton Dickinson).
DNA extraction was performed according to a previously
described salting-out protocol.5 The mutation analysis in-
cluded PCR amplification for each of the 27 exons of the
CFTR gene, with primers designed with the PrimerOut soft-
ware (primers sequences and conditions are available on
request). PCR fragments were submitted to SSCP-HA (Sin-
gle Strand Conformational Polymorphism and Heteroduplex
Analysis) in precast 12.5% polyacrylamide gels (GeneExel
GE, Amersham Biosciences, UK). Two SSCP-HA gels were
ran for each CFTR exon, one at 7OC and the other at 20OC.
Fragments with abnormal SSCP migration pattern were se-
lected to be sequenced on an AlfExpress (Pharmacia
Biotech, Sweden). The products of new PCR reactions, pu-
rified with the Concert Rapid PCR Purification System
(Gibco BRL) were used for sequencing with both forward
and reverse primers using the CyTM5 Thermo SequenaseTM
Dye Terminator Kit (Amersham Pharmacia Biotech).
For the analysis of the splice-junction site located in the
boundary of intron8/exon9 (IVS8) to access the number of
timines (5T, 7T or 9T), specific reverse primers were de-
signed for direct sequencing on AlfExpress, using the same
Dye Terminator Kit.
Table 1 shows the results found.
Case 1
The patient, a 30 year-old Caucasian man of Spanish
descent, was referred to the Center for Human Reproduc-
tion of the São Paulo University Medical College Hospital
by a pulmonologist due to chronic respiratory infections,
sinusitis and rhinitis since early childhood. Physical exami-
nation showed bilateral absence of vas deferens (CBAVD)
and a cyst on the head of the right epididymus. Seminal
analysis revealed azoospermia and low volume of ejacu-
late (<1mL) secondary to bilateral hypoplastic seminal vesi-
cles identified by transrectal ultrasound. The abdominal ul-
trasound showed normal topic kidneys and the sweat test
showed normal chloride concentration.
The new mutation found in the patient is an AGC to AGG
change in DNA leading to a serine-to-arginine substitution
at position 753 (S753R) in the CFTR protein; S753 is a con-
sensus phosphorylation site in the regulatory domain of
CFTR protein.6 No other classical CFTR mutation was found,
but a 5T allele was identified in intron 8 (IVS8-5T) together
with an IVS8-9T in the other allele. In exon 10 a M470V
polymorphism was found in heterozygosis, corresponding to
a methionine to valine substitution at protein position 470.
Case 2
Two brothers of the typical mixed ethnicity found in a
considerable percentage of Brazilians were referred from a
University Hospital to be screened for CFTR mutations. The
patients came with diagnosis of azoospermia and CBAVD.
Ultrasound showed normal topic kidneys and left seminal
vesicle agenesis in both brothers. The sweat chloride con-
centration was normal (24nmol/L) for the older brother and
borderline (45nmol/L) for the younger. No gastrointestinal
or pulmonary phenotype was present in both brothers.
A glycine-to-tryptophan substitution at protein position
149 (G149W) was detected in both brothers. We requested
the parents to be tested and the same mutation was found
in the mother. A third brother, with unilateral duplication
of vas deferens diagnosed at the time of his vasectomy, was
also tested but no mutation was found.
Both brothers had no other CFTR classical mutation but
were heterozygotes to the IVS8-5T allele and to other
polymorphisms: the M470V in exon 10 and the 2694T>G
in exon 14a, the later of unknown physiological conse-
quences.
Table 1 – Novel mutations and polymorphisms leading to
CFTR gene dysfunction in CBAVD patients.
Case 1 2a 2b
Age 30y 32y 27y
mutation S753R G149W G149W
IVS8-Tn 5T/9T 5T/7T 5T/7T
IVS8-TGm 10TG/12TG 10TG/11TG 10TG/11TG
polymorphisms M470V M470V M470V
2694T>G 2694T>G
Sweat chloride* 26nmol/L 24nmol/L 45nmol/L
Seminal Vesicles right hypoplastic normal normal
left hypoplastic agenesis agenesis
*ref: normal<30nmol/L; borderline 30-60nmol/L; high >60nmol/L
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DISCUSSION
Infertility is an important health problem, affecting 10%
of all men in reproductive age around the world. Among
the causes of infertility, 10% are due to CBAVD and are
associated to mutations in the CFTR gene.7 A large body
of evidence proved that CBAVD represents an atypical form
of CF8, and are also associated to mutations in the CFTR
gene9 or better called CFTR dysfunction.2 It is therefore sug-
gested that men who have CBAVD should be considered
for CF screening prior to ICSI procedure, despite a nega-
tive family history of CF. Because of the high carrier fre-
quency of about 1 in 25 for CFTR mutations in the general
population,10 when CBAVD is a clinical feature and the cou-
ple is considering MESA or TESE with ICSI, genetic
counseling is recommended and screening is proposed to
the female only if the male proves to be a carrier. If both
partners are CF carriers, the reproductive technology should
include pre-implantation genetic diagnosis (PGD) and
transfer of mutation-free embryos. Because ICSI might by-
pass the normal reproductive constraints of infertile men,
counseling of these couples requesting IVF with ICSI is vi-
tally important in order to help them understand the el-
evated risk for CF and/or infertility in their offspring, and
to help them to cope with the diagnosis.
To determine which tests actually might prove benefi-
cial to patients, both individually and collectively, cost-ben-
efit ratios, in addition to clinical and preventive implica-
tions, should be weighed as part of patient counseling. The
currently recommended screening panels of mutations in
the CFTR gene do not detect all disease-associated muta-
tions and are even less effective in detecting the less fre-
quent mutations associated to the CBAVD phenotype, spe-
cially in heterogeneous populations like Brazilian. Only an
extensive CFTR gene screening can detect rare mutations
that are not found with conventional screenings and com-
mercial tests, and can thus improve the diagnosis and care
of CF and CAVD and prevention of new cases with the use
of reproductive technologies.
In our study, we performed a screening of all the exons
and splicing of sites of interest of the CFTR gene in eight-
een CBAVD patients and two novel mutations were de-
tected: a serine-to-arginine at an alternative phosphoryla-
tion site in the regulatory domain (S753R), and a glycine-
to-tryptophan substitution at position 149 (G149W) in the
second intracellular domain of the CFTR protein.
Structural and functional studies of the CFTR channel
carrying the serine substitution at position 753 found in case
1 are not yet available and so its impact on the CFTR chan-
nel function is unknown. Considering the clinical presen-
tation of the patient, S753R might not be a polymorphism
once CBAVD was present together with a clear pulmonary
phenotype, although not together with sweat-chloride eleva-
tion. Besides, S753 is one of the ten serine residues sub-
mitted to phosphorylation (one in the NBD1 S-422 and nine
in the R domain S-660, -670, -700, -712, -737, -753, -768,
-795, -813) to exert the primary control of activation of Cl-
conductance.27
The second novel mutation found was a G149W. A dif-
ferent mutation (G149R) at the same position was previ-
ously reported in a CBAVD patient11 but was not found in
normal individuals nor in CF patients tested, placing the
G149R in the category of Class V mutation usually associ-
ated to the CBAVD phenotype.11 The G to W substitution
described here is probably even milder than G to R, once
glycine and tryptophan are both not polar amino acids. The
presence of the same mutation in both brothers and the bor-
derline sweat-chloride level found in one of them, favor
G149W as a novel CBAVD Class V CFTR mutation.
The three patients had no other CFTR mutation but all
were also heterozygotes for the IVS8-5T allele and for the
M470V polymorphism; the two brothers were also
heterozygotes for a 2694T>G polymorphism in exon 14a.
The 5T variant in intron 8 of the CFTR gene is the most
frequent mutation associated to the CBAVD phenotype12 and
can be the sole cause of disease, such as CBAVD.12,13 The
5T allele leads to a higher proportion of transcripts lack-
ing exon 9 than the two other alleles, 7T and 9T. However,
this 5T variant has incomplete penetrance and variable
expressivity, suggesting that some other regulatory factors
may modulate the splicing of exon 9. 14
The association of the IVS8-5T allele in the 3 patients,
once again places the IVS8-5T allele as a CBAVD causing
genotype variation as extensively reported in the literature.
In Italy more than 20,000 control subjects and over 1,800
in the infertile situation were tested; 94% of the 5T alleles
were found in the infertile group of men affected by
CBAVD, and one 5T allele together with a CFTR muta-
tion are three times more frequent in infertile men. 15
For national policies of CF prevention such as the one
adopted in Italy15, it is acceptable to include only the most
frequent mutations present in the population, which allows
a 90% detection rate. Nevertheless, when a patient presents
with infertility, a thorough mutation search has to be un-
dertaken because even in homogeneous populations, the
mutations associated to CBAVD are rare.
The carrier rate and mutation frequencies vary widely
in different populations so that screening tests with high
detection rates for CFTR mutations have to consider the
population ethnicity. In heterogeneous populations such as
the Brazilian, complete genetic information is currently
lacking to build up solid population-based CFTR screen-
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ing programs that could enable adequate carrier detection
of either typical or atypical CF patients and their family
members. Identification of new mutations is clinically rel-
evant not only to birth defects prevention using reproduc-
tive technologies, but also to a better molecular understand-
ing of the involvement of the CFTR gene in the urogenital
phenotype of these men. Additionally, the approach will
help to develop new strategies to improve and extent the
number of mutations screened.
Counseling a CBAVD patient with a CFTR mutation
and an IVS8-5T allele is a difficult task because it is not
possible to determine whether this genotype would lead to
the same phenotype in the child, or if the phenotype would
be as severe. The fact that the children born with the help
of ICSI may be completely healthy, even though carrying
the same CBAVD genotype of the father should not dis-
courage the indication of CFTR screening. Even for those
couples in which both are carriers, the biological paternity
can be obtained by ICSI but, in these cases, preimplantation
genetic diagnosis ought to be performed, with blastomere
biopsy of each embryo produced and transfer of healthy
embryos only.
Assisted Reproduction underscores the importance of
mutational analysis of the CFTR gene when an infertile cou-
ple is seeking for IVF, but we strongly recommend the
screening of the whole CFTR gene for all infertile couples,
man and wife, as part of the workup before assisted repro-
duction with IVF-ICSI.
RESUMO
Pieri PC, Missaglia MT, Roque JA, Moreira-Filho CA,
Hallak J. Mutações novas no gene CFTR de pacientes
brasileiros portadores de agenesia dos vasos deferentes:
dificuldades no aconselhamento. Clinics. 2007;62(4):385-
90.
OBJETIVO: Pesquisar mutações em toda a extensão do
gene que causa a Fibrose Cística (CFTR) de homens
brasileiros inférteis por agenesia congênita dos vasos
deferentes, com a finalidade de prevenir a transmissão de
mutações em CFTR à prole com o uso das tecnologias de
reprodução assistida.
MÉTODOS: Foram desenhados oligonucleotídeos
específicos para realização de reação de polimerização em
cadeia (PCR) para cada um dos 27 exons e sítios de
processamento de interesse no gene CFTR. O PCR foi
seguido pela técnica de SSCP-HA (polimorfismos de
conformação no DNA de fita simples e na formação de
heteroduplexes) em géis pré-fabricados de poliacrilamida
a 12,5% em duas temperaturas, 7OC e 20OC. Os fragmentos
com padrão alterado na migração do SSCP foram
submetidos a seqüenciamento automatizado.
RESULTADOS: Foram identificadas duas mutações novas
com alteração de aminoácidos (S753R and G149W) em 3
pacientes (dois irmãos) juntamente com o alelo IVS8-5T
em heterozigose.
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CONCLUSÕES: O rastreamento básico de mutações típicas
da Fibrose Cística não inclui as mutações atípicas associadas
à ausência dos deferentes. Desta forma, quando esses testes
resultam normais, ainda assim existe um risco genético de
crianças afetadas serem geradas com auxílio das Assisted
Reproduction Technologies. Por este motivo, recomenda-se
que a pesquisa de mutações em todo o gene CFTR seja o
exame a ser oferecido para todos os casais inférteis em que
o homem seja portador de agenesia dos vasos deferentes,
antes da realização de reprodução assistida.
UNITERMOS: Vasos deferentes. CFTR. Infertilidade
masculina. Azoospermia. Prevenção.
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